Subtype
Prostate Carcinoma
CI-CAN-00006533Explore in graph →
429 active trials16 approved drugs20 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00006533Explore in graph →
Clinical trials
1,176 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (184)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07073794 | Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer | recruiting | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT05658003 | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | active not recruiting | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 23, 2026 |
| clinicaltrials |
| NCT06798558 | Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy | recruiting | Phase 2 | 54 | Hackensack Meridian HealthOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03412396 | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | active not recruiting | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT05888532 | 64Cu-GRIP B in Patients With Advanced Malignancies | recruiting | Phase 1 / Phase 2 | 91 | Rahul AggarwalOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06173362 | Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer | recruiting | Phase 2 | 75 | University of California, DavisOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT06288113 | Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial | recruiting | Phase 2 | 40 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07142551 | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response | recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06216249 | Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) | recruiting | Phase 2 | 90 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06330805 | Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer | recruiting | Phase 2 | 70 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07285057 | Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance | recruiting | Phase 2 | 120 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05720130 | Phase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study). | recruiting | Phase 1 / Phase 2 | 100 | AdvanCell Pty LimitedINDUSTRY | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04754191 | Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer(ENCORE) | active not recruiting | Phase 2 | 34 | University of UtahOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05320406 | RElugolix VErsus LeUprolide Cardiac Trial(REVELUTION) | active not recruiting | Phase 2 | 94 | Emory UniversityOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT04704505 | Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)(BAT-RAD) | recruiting | Phase 2 | 47 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 2 | Feb 6, 2026 | clinicaltrials |
| NCT03902951 | Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | active not recruiting | Phase 2 | 28 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT05534646 | Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 100 | Edwin Posadas, MDOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT05806515 | Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | recruiting | Phase 2 | 44 | SWOG Cancer Research NetworkNETWORK | 1 | Jan 29, 2026 | clinicaltrials |
| NCT04734730 | Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | recruiting | Phase 2 | 70 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT05924672 | Efficacy of Ra-223 in PSMA PET Optimally Selected Patients | active not recruiting | Phase 2 | 2 | University of California, San FranciscoOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06334432 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 466 | Nuvation Bio Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04777071 | An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer | active not recruiting | Phase 2 | 141 | University of WashingtonOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05570994 | 177Lu-HTK03170 in mCRPC With PSMA Positive Disease | enrolling by invitation | Phase 1 / Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT06866938 | Study of Re-treatment With [177Lu]Lu-PSMA in Men With Metastatic Castration Resistance Prostate Cancer(ReaLuP) | recruiting | Phase 2 | 58 | Hospices Civils de LyonOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT07310355 | 68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer | not yet recruiting | Phase 1 / Phase 2 | 49 | Chengdu StarRay Therapeutics Co., LtdINDUSTRY | 0 | Dec 30, 2025 | clinicaltrials |
| NCT06155084 | A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients | recruiting | Phase 1 / Phase 2 | 84 | Hinova Pharmaceuticals Inc.INDUSTRY | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07251829 | Neoadjuvant Embolization and Cytoreduction in Prostate Cancer | not yet recruiting | Phase 2 | 35 | Srinivas RamanOTHER | 0 | Nov 26, 2025 | clinicaltrials |
| NCT06126731 | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | recruiting | Phase 1 / Phase 2 | 39 | Institute of Cancer Research, United KingdomOTHER | 2 | Nov 24, 2025 | clinicaltrials |
| NCT07164794 | Memantine Hydrochloride in Prostate Cancer Patients | not yet recruiting | Phase 2 | 15 | Bin XuOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT03541850 | Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery | active not recruiting | Phase 2 | 92 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT05779943 | Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer | active not recruiting | Phase 2 | 20 | Emory UniversityOTHER | 1 | Oct 27, 2025 | clinicaltrials |
| NCT05869682 | Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy | recruiting | Phase 2 | 210 | City of Hope Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT07179783 | Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) | recruiting | Phase 2 | 28 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07172126 | Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets | not yet recruiting | Phase 1 / Phase 2 | 291 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06134232 | Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T(ProvONE) | recruiting | Phase 2 | 400 | DendreonINDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT06241846 | A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | recruiting | Phase 2 | 100 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Aug 27, 2025 | clinicaltrials |
| NCT04319783 | Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA(DECREASE) | active not recruiting | Phase 2 | 65 | Trans Tasman Radiation Oncology GroupOTHER | 2 | Aug 21, 2025 | clinicaltrials |
| NCT04015622 | PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA(PROTRACT) | active not recruiting | Phase 2 | 100 | British Columbia Cancer AgencyOTHER | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT07104617 | Study of TY-302 Capsules Combined With Abiraterone in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） | not yet recruiting | Phase 1 / Phase 2 | 48 | TYK Medicines, IncINDUSTRY | 1 | Aug 5, 2025 | clinicaltrials |
| NCT06049355 | EMBRACE: Exercising Together | recruiting | Phase 2 | 400 | OHSU Knight Cancer InstituteOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06383052 | A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC | active not recruiting | Phase 1 / Phase 2 | 30 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06972628 | Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617 | recruiting | Phase 2 | 30 | Ebrahim S DelpassandOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06971211 | Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC(PARTOM) | recruiting | Phase 2 | 40 | Jianbin BiOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04253262 | A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 13 | Brown UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT03689699 | Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer (MAGIC-8) | active not recruiting | Phase 1 / Phase 2 | 59 | Mark SteinOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT06702995 | Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 1 / Phase 2 | 307 | Evopoint Biosciences Inc.INDUSTRY | 1 | Apr 20, 2025 | clinicaltrials |
| NCT06480110 | Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer | recruiting | Phase 1 / Phase 2 | 30 | Rigshospitalet, DenmarkOTHER | 1 | Apr 13, 2025 | clinicaltrials |
| NCT05340374 | Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer(LuCAB) | active not recruiting | Phase 1 / Phase 2 | 35 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Apr 6, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 25, 2026source: clinicaltrials